Theravance Biopharma, Inc. (NASDAQ: TBPH)
$8.8300
-0.2200 ( -1.78% ) 99.0K
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Market Data
Open
$8.8300
Previous close
$9.0500
Volume
99.0K
Market cap
$431.75M
Day range
$8.6850 - $9.5450
52 week range
$7.4400 - $10.4400
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | May 10, 2024 |
4 | Insider transactions | 1 | May 10, 2024 |
4 | Insider transactions | 1 | May 10, 2024 |
4 | Insider transactions | 1 | May 10, 2024 |
4 | Insider transactions | 1 | May 10, 2024 |
4 | Insider transactions | 1 | May 10, 2024 |
8-k | 8K-related | 13 | May 09, 2024 |
4 | Insider transactions | 1 | May 03, 2024 |
def | Proxies and info statements | 7 | Apr 05, 2024 |
4 | Insider transactions | 1 | Apr 04, 2024 |